Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer
Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals' revenues.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Switzerland Health